REGENXBIO closes upsized $107.8M equity offering at $9.00/share, a 20% discount

summarizeSummary

An upsized $107.8 million equity offering closed at $9.00 per share, a 20% discount to market, with underwriters exercising the full overallotment option. The raise provides critical funding but dilutes existing shareholders substantially.

check_boxKey Events · Financing and Capital Events · RGNX

• Upsized Offering Closes

  The transaction sold 11,671,139 common shares at $9.00 and 1,111,111 pre-funded warrants at $8.9999, with underwriters exercising the full 1,667,250-share overallotment option.

• Net Proceeds Reach ~$107.8M

  After underwriting discounts and expenses, net proceeds are approximately $107.8 million, up from the ~$94 million initially disclosed due to the overallotment exercise.

• Deep Discount to Market

  Priced at $9.00 per share, the offering represents a 20% discount to the $10.01 stock price as of today, reflecting the company's urgent need for capital despite recent positive clinical news.

• Dilution Impact

  The 11.67 million new shares plus 1.11 million warrant shares represent roughly 25% dilution to existing shareholders, based on approximately 51 million shares outstanding prior to the offering.

auto_awesomeAnalysis · RGNX · Life Sciences

A heavily dilutive equity raise has been finalized, with 11.67 million shares sold alongside pre-funded warrants covering an additional 1.11 million shares — all at $9.00, a 20% discount to the $10.01 market price. Underwriters exercised the full overallotment, pushing net proceeds to approximately $107.8 million. The capital extends the cash runway for a company that faced going-concern doubts just two months ago, but existing shareholders absorb significant dilution. The offering lands amid a volatile period: positive Phase III Duchenne data in May, a $100M AbbVie milestone in June, and now this discounted raise — a mixed signal of clinical promise and urgent funding needs.